An internal standard for the quantification of enzalutamide
Related Products
Unlabeled Version(s)
11596Enzalutamide
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Enzalutamide-d3

Item No. 45044

Technical Information
Formal Name
4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-(methyl-d3)-benzamide
CAS Number
1443331-82-5
Molecular Formula
C21H13D3F4N4O2S
Formula Weight
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
Chloroform: Slightly solubleEthyl Acetate: Slightly soluble
SMILES
S=C1N(C2=CC(F)=C(C=C2)C(NC([2H])([2H])[2H])=O)C(C)(C(N1C3=CC(C(F)(F)F)=C(C=C3)C#N)=O)C
InChi Code
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
InChi Key
WXCXUHSOUPDCQV-HPRDVNIFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Enzalutamide-d3 is intended for use as an internal standard for the quantification of enzalutamide (Item No. 11596) by GC- or LC-MS. Enzalutamide is a non-steroidal androgen receptor antagonist (IC50 = 36 nM).1,2 It reduces the efficiency of nuclear translocation of the androgen receptor and impairs both its binding to DNA and the recruitment of coactivators.1 It is orally available and induces tumor regression in mouse models of castration-resistant human prostate cancer.1 Formulations containing enzalutamide have been used in the treatment of prostate cancer.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Tran, C., Ouk, S., Clegg, N.J., et alDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).

    2. Jung, M.E., Ouk, S., Yoo, D., et alStructure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J. Med. Chem. 53(7), 2779-2796 (2010).